Leal Therapeutics Appoints Johannes Tauscher as Chief Medical Officer and Raymond Jordt as Chief Business Officer

Leal Therapeutics raises $30 million in Series A financing led by SV Health Investors' Dementia Discovery Fund to develop therapies for neurodegenerative disorders.

Leal Therapeutics raised $45M in a Series A funding round led by Newpath Partners to advance its pipeline of therapeutics for central nervous system disorders.

With $39M in seed funding, Worcester startup aims to develop ALS, schizophrenia treatments

Leal Therapeutics is a biotechnology company dedicated to developing novel neuro-metabolic therapeutics for patients with high-need central nervous system disorders. Leal was launched in 2021 and is headquartered in Worcester, Mass. Leal's lead programs address the critical intersection between CNS and metabolic disorders. The Leal team has particular expertise in CNS therapeutic development, as w

Leal Therapeutics

Funding history

Recent signals